Syndax Pharmaceuticals Inc

Guggenheim analyst Brad Canino lowered the price target for Syndax Pharmaceuticals to $31 from $34 while maintaining a Buy rating, reflecting revised acute myeloid leukemia market assumptions after new insights on revumenib's post-transplant maintenance duration from recent medical conference updates. The adjustment also considered recent commercial updates from Syndax and Kura Oncology. Separately, Syndax announced the publication of Phase 1/2 SAVE trial results evaluating an oral combination of Revuforj, decitabine/cedazuridine, and venetoclax in relapsed or refractory acute myeloid leukemia patients with NPM1 mutations, KMT2A rearrangements, or NUP98 rearrangements. The study enrolled 42 patients and showed an overall response rate of 88% with a 71% composite complete remission rate, demonstrating activity across genetic subgroups and a generally manageable safety profile.

Syndax Pharmaceuticals ranks as the most likely biotech takeover target following AbbVie's acquisition of Apogee Therapeutics, according to a Wall Street analysis. With a market cap of roughly $1.71 billion, Syndax is the smallest of three highlighted Nasdaq-listed firms and already has two FDA-approved drugs, Revuforj and Niktimvo, generating $64.86 million in total first-quarter revenue, up 223.6% year over year. Its co-commercialization partner Incyte is named as the most logical acquirer, while Nektar Therapeutics and Viking Therapeutics are seen as less urgent targets due to their larger cash reserves and market caps. The Apogee deal has reignited merger and acquisition speculation across the biotech sector, with buyers seeking late-stage clinical data, large addressable markets, and strategic fit in immunology, obesity, or oncology.